Danaher Co. (NYSE:DHR) Shares Sold by Estabrook Capital Management

Estabrook Capital Management lessened its holdings in Danaher Co. (NYSE:DHR) by 73.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 210 shares of the conglomerate’s stock after selling 584 shares during the period. Estabrook Capital Management’s holdings in Danaher were worth $52,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Cape Investment Advisory Inc. acquired a new stake in Danaher during the 4th quarter valued at $25,000. Tsfg LLC boosted its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter valued at $25,000. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth about $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the 1st quarter valued at about $30,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on DHR shares. Evercore ISI decreased their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. TD Cowen raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Finally, Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Trading Down 1.4 %

Shares of DHR stock opened at $272.63 on Friday. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The firm’s 50 day moving average price is $267.62 and its two-hundred day moving average price is $257.16. The stock has a market cap of $201.93 billion, a price-to-earnings ratio of 46.21, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company earned $2.05 EPS. The firm’s revenue was down 2.9% on a year-over-year basis. On average, analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.